Identifying genomic changes and therapeutic vulnerabilities in neuroblastoma
Neuroblastoma is the most common extra cranial solid tumor in children. Less than 50% of patients with high-risk neuroblastoma will survive long-term with current therapies, and survivors are at risk for serious treatment-related late toxicities. The goal of the lab is to discover new therapeutic targets and biomarkers to risk stratify patients and guide therapy selection. To accomplish this, research in the lab focuses on understanding the underlying genomic abnormalities in high-risk neuroblastoma.
Former lab member Emma Wilkinson joined the Committee on Cancer Biology at the University of Chicago last September!